News & Updates

Original New Drug Application Approvals by US FDA (16-30 September 2021)

04 Oct 2021

New drug applications approved by US FDA as of 16 -30 September 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2021)

04 Oct 2021

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

04 Oct 2021

Treatment with azathioprine helps prevent relapse of autoimmune pancreatitis, according to the results of a systematic review and meta-analysis.

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

04 Oct 2021

Mepolizumab add-on shrinks nasal polyp in CRSwNP

03 Oct 2021 by

Add-on treatment with the anti-IL-5 biologic mepolizumab significantly reduces nasal polyp size and nasal obstruction, along with less need for surgery and systemic corticosteroid use compared with standard care alone in patients with recurrent, refractory, and severe chronic rhinosinusitis with nasal polyps (CRSwNP), the SYNAPSE study shows.

Mepolizumab add-on shrinks nasal polyp in CRSwNP

03 Oct 2021

Dose escalation intolerance disrupts maintenance therapy of children with ALL

03 Oct 2021

Only a few children with acute lymphoblastic leukaemia (ALL) treated with mercaptopurine (6MP) and methotrexate (MTX) complete their maintenance therapy without interruptions at the current dose escalation schedules outlined by the Children’s Oncology Group protocols, a study has shown.

Dose escalation intolerance disrupts maintenance therapy of children with ALL

03 Oct 2021

Drug interactions in breast cancer therapy may harm patients

02 Oct 2021

Several drug-drug interactions (DDIs) found in breast cancer treatment may lead to adverse consequences on patient health and therapeutic outcomes, suggests a study.

Drug interactions in breast cancer therapy may harm patients

02 Oct 2021

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

02 Oct 2021

Tyrosine kinase inhibitors (TKIs) are a safe and effective first-line treatment for metastatic renal cell cancer (mRCC), confirms a Turkey study. In addition, no significant difference has been observed among three TKI agents (sunitinib, pazopanib, and sorafenib) in terms of treatment duration, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

02 Oct 2021

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

02 Oct 2021

Antiplatelet therapy guided by platelet function monitoring helps prevent thromboembolic events among patients with unruptured intracranial aneurysm who have undergone stent placement but at the cost of higher minor or minimal bleeding events, according to data from an open-label study.

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

02 Oct 2021

COVID-19 vacc side effects: Fewer than expected?

01 Oct 2021 by

A community-based study from the UK showed that the rate of systemic side effects is relatively low following vaccination with the BNT162b2 or ChAdOx1 nCoV-19 COVID-19 vaccines.

COVID-19 vacc side effects: Fewer than expected?

01 Oct 2021

Pimavanserin for dementia-related psychosis: to continue or not?

01 Oct 2021 by

In individuals with dementia-related psychosis (DRP) who had a response to the oral 5-HT2A* inverse agonist and antagonist pimavanserin, an atypical antipsychotic agent, the risk of relapse was lower among those who continued the drug vs those who stopped it, the phase III HARMONY trial suggests.

Pimavanserin for dementia-related psychosis: to continue or not?

01 Oct 2021

Bimekizumab shows promise for hidradenitis suppurativa

30 Sep 2021 by

The monoclonal IgG1 antibody bimekizumab, which selectively inhibits both interleukin(IL)-17A and 17F, demonstrated clinically meaningful improvements for moderate-to-severe hidradenitis suppurativa (HS) or acne inversa, a phase II study suggests.

Bimekizumab shows promise for hidradenitis suppurativa

30 Sep 2021

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (16-30 September 2021)

Original New Drug Application Approvals by US FDA (16-30 September 2021)

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

Mepolizumab add-on shrinks nasal polyp in CRSwNP

Mepolizumab add-on shrinks nasal polyp in CRSwNP

Dose escalation intolerance disrupts maintenance therapy of children with ALL

Dose escalation intolerance disrupts maintenance therapy of children with ALL

Drug interactions in breast cancer therapy may harm patients

Drug interactions in breast cancer therapy may harm patients

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

COVID-19 vacc side effects: Fewer than expected?

COVID-19 vacc side effects: Fewer than expected?

Pimavanserin for dementia-related psychosis: to continue or not?

Pimavanserin for dementia-related psychosis: to continue or not?

Bimekizumab shows promise for hidradenitis suppurativa

Bimekizumab shows promise for hidradenitis suppurativa